IGF2 loss-of-function T2D protective variant
Supplementary Figure legends

Supplementary Figure 1:
Genotype integration and imputation strategy. The sample was divided into two cohorts according to the technologies used to ascertain the genetic variants. A subset of the samples (Dataset 1) was genotyped on the OMNI2.5 (1) and exome chip arrays. Dataset 2 was also ascertained by whole-exome sequencing and was used as a Mexican specific reference panel (2) . We imputed both the variants of the whole-exome-sequencing Mexican specific reference panel and the 1000G (phase 3, release June 2014) variants into the samples that did not have whole-exome sequencing information. We only imputed 1000G (phase 3) variants into the samples that had wholeexome sequencing, OMNI2.5 and exome chip genotypes. We then performed the association testing separately of each dataset and meta-analyzed both results. represent the estimated OR and 95% confidence interval of the rs149483638 after adding, in a sequential manner each of the low-frequency variants into the model. As shown in the plot, the rs149483638 association was did not disappear when adding up to 50 lowfrequency variants into the model, which suggest that this signal is not driven by the presence of low-frequency variants strongly associated with the disease. 
Supplementary Figure 2: Characterization of the IGF2-INS-TH locus. Regional plot is shown for the IGF2-INS-TH and KCNQ1, without conditioning (a)
.
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Detailed description of study participants
Diabetes in Mexico Study (DMS):
Individuals were enrolled in the study, recruited from two tertiary level institutions (IMSS and ISSSTE) located in Mexico City. The diagnosis of T2D was made based on ADA criteria. 811 unrelated healthy subjects older than 45 years and with fasting glucose levels below 100 mg/dL were classified as controls. 569 unrelated individuals, older than 18 years, with either previous T2D diagnosis or fasting glucose levels above 125 mg/dL were included as T2D cases. Individuals with fasting glycemia between 100-125 mg/dL were excluded. Informed consent was obtained from all participants. The study was conducted with the approval of the Ethics and Research Committees of all institutions involved. Genomic DNA was purified from whole blood samples using a modified salting-out precipitation method (Gentra Puregene, Qiagen Systems, Inc., Valencia, CA, USA).
Clinical history of these individuals was manually reviewed and incidence of difference diseases was used for the phenome-wide association analysis.
Mexico City Diabetes Study (MCDS):
The Mexico City Diabetes Study is a population based prospective investigation. All 35-64 years of age men and non-pregnant women residing in the study site (low income neighborhoods equivalent to 6 census tracks with a total population of 15,000 inhabitants) were interviewed and invited to participate in the study. We had a response rate of 67% for the initial exam. Diagnostic criteria for type 2 diabetes were recommended by the ADA. Fasting glucose 126 mg/dL or more or 2 hr post 75 gr of glucose load 200 or more. If a participant was diagnosed as diabetic by a physician and was under pharmacologic therapy for diabetes he was considered as diabetic regardless the blood glucose levels. The study was conducted with the approval of the Ethics and Research Committees IGF2 loss-of-function T2D protective variant of all institutions. Informed consent was obtained from all participants. Genomic DNA was extracted from whole blood using the QIAmp 96 DNA Blood Kit (12) (Qiagen, Cat. No. 51162).
Multiethnic Cohort (MEC):
The MEC consists of 215,251 men and women in Hawaii and Los Angeles, and comprises mainly five self-reported racial/ethnic populations: African Americans, Japanese Americans, Latinos, Native Hawaiians and European Americans (3). Between 1993 and 1996, adults between 45 and 75 years old were enrolled by completing a 26-page, self-administered questionnaire asking detailed information about dietary habits, demographic factors, level of education, personal behaviors, and history of prior medical conditions (e.g., diabetes). Potential cohort members were identified IGF2 loss-of-function T2D protective variant T2D controls (as defined below) with undiagnosed T2D, as well as the percentage of identified diabetes cases with T1D rather than T2D. Based on the OSHPD database <3% of T2D cases had a previous diagnosis of T1D. We did not use these sources to identify T2D cases because they did not include information on diabetes medications, one of our inclusion criteria for cases (see below).
In the MEC, diabetic cases were defined using the following criteria: (a) a self-report of diabetes on the baseline questionnaire, 2nd questionnaire or 3rd questionnaire; and (b) self-report of taking medication for T2D at the time of blood draw; and (c) no diagnosis of T1D in the absence of a T2D diagnosis from the OSHPD (California Residents). Controls were defined as: (a) no self-report of diabetes on any of the questionnaires while having completed a minimum of 2 of the 3 (~80% of controls returned all 3 questionnaires); and (b) no use of medications for T2D at the time of blood draw; and (c) no diabetes diagnosis (type 1 or 2) from the OSHPD, HMSA or KPH registries. To preserve DNA for genetic studies of cancer in the MEC, subjects with an incident cancer diagnosis at time of selection for this study were excluded. Controls were frequency matched to cases on sex, ethnicity and age at entry into the cohort (5-year age groups) and for Latinos, place of birth (U.S. Control subjects were recruited from a cohort of adults aged 45 years or older among government employees, blue collar workers and subjects seeking for attention in medical units for any condition besides those considered as exclusion criteria (see below). Normoglycemic status was defined as having a fasting plasma glucose concentration < 100 mg/dL and no previous history of hyperglycemia, gestational diabetes or use of metformin.
Patients were interviewed following a standardized questionnaire; it included the medical history, a previously validated, three days food record and a physical activity registry. In addition a blood sample (after 9-12 hours of fasting) was obtained. The questionnaire included demographic, socio-economic and medical history of the patients and their family. Blood pressure, height, waist circumference and weight must be measured in the same visit. For taking blood pressure, systolic and diastolic pressure were recorded using a mercury sphygmomanometer; subjects remained seated and at rest for five minutes before measuring. IGF2 loss-of-function T2D protective variant individuals with drug addictions, the use of systemic corticosteroids in pharmacologic doses (intravenous, oral or injectable, including injections in the joints) were exclusion criteria also.
Replacement dosage of systemic corticosteroids (up 7.5 mg/day of prednisone or 30 mg/day of hydrocortisone or its equivalent; as well as inhaled or topical corticosteroids) was allowed into the study. Other exclusion criteria were: active liver disease (defined as AST (SGOT) or ALT (SGPT) > 2.0x upper limit of the normal range, alkaline phosphatase (ALK-P) > 1.5x upper limit of the normal range or total bilirubin > 1.5x upper limit of the normal range), significant renal dysfunction (defined as serum creatinine > 1.7 upper limit of the normal range or nephrotic syndrome), any history of malignancy (except for basal cell skin carcinoma) and uncontrolled depression or psychosis.
Informed consent was obtained from all participants. The study was conducted with the approval of the Ethics and Research Committees of all institutions. Genomic DNA was extracted from whole blood using the QIAmp 96 DNA Blood Kit (12) (Qiagen, Cat. No. 51162).
Pima Native Americans
Diabetes was diagnosed by 1997 American Diabetes Association criteria; details for this cohort have been described previously (4) . rs149483638 was analyzed in 3,199 full heritage Pima Indians selected from a longitudinal study (4) . These individuals included 1,847 women and 1,352 men; mean age at examination was 40.6 (±16. 
The Type 2 Diabetes Genetic Exploration by Next-generation sequencing in multi-Ethnic Samples
T2D-GENES Consortium (T2D-GENES):
All the exons were sequenced in 12,294 additional individuals as part of the whole-exome sequencing studies performed through the Genetics of Type 2 Diabetes (GoT2D) and Type 2 Diabetes Genetic Exploration by Next-generation sequencing in multi-Ethnic Samples (T2D-GENES) consortia. Individuals were selected spanning 5 ethnicities: European (the FUSION study (5)[FUSION], the METSIM study (6) [METSIM], KORA-gen (7) IGF2 loss-of-function T2D protective variant County]). Data generation and processing was performed in an identical fashion as for the initial sequencing experiment, although target capture was performed with the Agilent SureSelect Human All Exon platform rather than a custom hybrid capture array.
Diabetes in Mexico Study 2 (DMS2):
This cohort included 1228 unrelated volunteers from different ethnic groups along Mexico (Tarahumara, Yaqui, Mayo, Mixteco, Náhuatl, Otomí, Chinanteco, Mixe, Zapoteco, Mazateco, Totonaco, Huasteco, Maya, Kanjobal, Mame, Poptijacalteco, Kaqchikel, Tojolabal, Chontal, Huave). Inclusion criteria were that they identified themselves as indigenous, both parents and their four grandparents speak the same native language and were born in the same community. The diagnosis of T2D was made based on ADA criteria. Seven hundred eighty-three unrelated healthy subjects older than 45 years and with fasting glucose levels below 100 mg/dL were classified as controls. Four hundred forty-five unrelated individuals, older than 18 years, with either previous T2D diagnosis or fasting glucose levels above 125 mg/dL were included as T2D cases. Individuals with fasting glucose levels between 100-125 mg/dL were excluded. Informed consent was obtained from all participants. The study was conducted with the approval of the Ethics and Research Committees of all institutions involved. Genomic DNA was purified from whole blood samples using a modified salting-out precipitation method (Gentra Puregene, Qiagen Systems, Inc., Valencia, CA, USA). Genotyping of the rs149483638 variant was performed using a custom Clinical history of these individuals was manually reviewed and incidence of difference diseases was used for the phenome-wide association analysis.
San Antonio Mexican American Family Studies (SAMAFS):
Genotypes for rs11564732, which showed an r2=0.89 with rs149483638 in our discovery sample, was carried out using the MassARRAY system (Sequenom, San Diego, CA). Variant assay primers were designed using Sequenom's online assay design tool in conjunction with their MassARRAY Assay Designer v4.0 software, to amplify ~100bp surrounding the variant for amplification in the The association analysis was carried out using FBAT, assuming the additive model and using the residuals resulting from regressing out age, age^2 and BMI (34). rs149483638 was genotyped as part of the Human Core Exome genotyping array from Illumina at the Genomics Platform at the Broad Institute. Genotyping and calling was performed as described below. Genotyping of rs149483638 was completed with high quality on the Human Core Exome genotyping arrays (99.9% call rate). The association between the outcome variables and the marker was tested using multivariable mixed model regression. All models were adjusted for age at randomization, sex, study site, and population stratification using principal components derived only from Hispanic and Amer-Indian subjects. Clinic was entered into the model as a random effect. In additional models, waist was added in addition to these covariates. Because of the low frequency of the minor allele in the other ethnic groups, only self-reported Hispanics (n=538) and American Indians (n=78) are included in the analysis. These two groups were analyzed together and then tested in stratified models as only the Hispanic group has individuals homozygous for the rare IGF2 loss-of-function T2D protective variant allele. Given the possibility that variants in IGF2 exhibit a parent-of-origin effect, besides the additive model (per allele effect) we also tested the homozygous extremes model (comparing CC vs TT) in order to reduce the noise of heterozygous subjects in cases parent-of-origin is present.
Diabetes Prevention Program
The natural log of ISI and the IGR was used in the analysis because their distributions are skewed.
Because these hypotheses represent confirmation of previous findings (and thus possess a high prior probability), a P value of 0.05 was considered statistically significant. Insulin sensitivity index (ISI), the reciprocal of insulin resistance by homeostasis model assessment, was calculated as 
Resource for Genetic Epidemiology Research on Adult Health and Aging (GERA)
GERA cohort data was obtained through dbGaP under accession phs000674.v1.p1 (36). The This protocol for genetic markers was performed twice, before and after sample exclusion.
For the individuals, we considered the following exclusion criteria: gender discordance, subject relatedness (pairs with ≥ 0.125 from which we removed the individual with the highest proportion of missingness), variant call rates ≥ 0.02 and population structure showing more than 4 standard deviations within the distribution of the study population according to the first seven principal components.
The presence of up to 18 medical conditions besides T2D was taken into account for the phenomewide association analysis. IGF2 loss-of-function T2D protective variant
We performed a two-stage imputation procedure, which consisted in pre-phasing the genotypes into whole chromosome haplotypes followed by imputation itself. The pre-phasing was performed using the SHAPEIT2 (37)tool, IMPUTE2 for genotype imputation and the SNPTEST (https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html#introduction) tool for association testing. GWIMp-COMPSs can incorporate the contribution of several reference panels, and in this work we used 1000 Genomes (1000G) Phase3 haplotypes (October, 2014) (38).
Association testing was performed by additive logistic regression using SNPTEST, and adjusting for the 7 derived principal components, age, and body mass index.
Exome chip SNP genotyping and quality control
The Genomics Platform at the Broad Institute (Cambridge, MA) received, QC'd and tracked DNA samples for Exome array processing. The exome array was designed in order to cover rare and lowfrequency coding variants identified through whole-exome sequencing studies of 12,031 individuals from different populations including 362 individuals of Hispanic ancestry.
The samples were plated into 96-well plates that included a quality control sample for processing on the Illumina HumanExome BeadChip (Illumina, Inc. San Diego, CA) using manufacturer's protocols. The arrays were scanned using Illumina iScans. Genotypes were called using three different calling algorithms: Illumina GenCall, Z-call (39) and Birdsuite (http://www.broadinstitute.org/science/programs/medical-and-populationgenetics/birdsuite/birdsuite-0).
Clusters were fit using the Birdseed algorithm to each genotyping plate independently. Genotypes with confidence below 99.9% were excluded from analysis (e.g. considered "missing" or "no-call" genotypes). Samples with low numbers of non-reference alleles (< ~20,000, depending on the cohort), low call rate (<99.3%) or unusually high heterozygosity (> ~0.05, depending on the cohort)
were removed from subsequent analysis; thresholds were chosen based on visual inspection of the 
RNA isolation from frozen tissue samples
RNA was extracted via the miRNeasy Mini Kit from Qiagen. This kit combines a phenol/guanidine-based lysis and a silica-membrane based purification. Tissue specimens were prepared and cut to 20-25 mg on a dry ice bath, then placed in 2 mL processing tubes containing
QIAzol lysis reagent and a steel bead. Tubes were then placed in the TissueLyser for 5 min at 25Hz
to lyse and homogenize the samples.
After homogenizing, tubes were incubated at room temperature for 5 min. 140 µl chloroform was then added to each tube containing homogenate. Samples incubated at room temperature for 2-3 min and were centrifuged at 12,000xg/4C for 15 min.
After centrifugation, the samples separated into 3 phases: an upper, colorless aqueous phase containing RNA, a white interphase, and a lower, red organic phase. The upper aqueous phase was carefully transferred to a new 1.5mL eppendorf tube (~350 µL). 525 µL of 100% ethanol was added to this phase and mixed thoroughly by pipetting up and down several times.
The entire sample, including any precipitate, was pipetted into RNeasy mini spin columns and then centrifuged for 15 s at 8000xg in order to collect and discard the flow-through. IGF2 loss-of-function T2D protective variant 700 µL Buffer RWT was then added to the RNeasy Mini spin column, centrifuged for 15s at 8000xg, and the flow through discarded.
500µL Buffer RPE was then pipetted onto the RNeasy Mini spin column and centrifuged for 15s at 8000xg. The flow through was again discarded Again 500 µL Buffer RPE was pipetted onto the RNeasy Mini spin column and centrifuged for 2 min at 8000xg.
The RNeasy Mini spin columns were then placed into new 2mL collection tubes and centrifuged at full speed for 1 min. This allowed the membrane to fully dry out, ensuring no ethanol was carried over during RNA elution.
For each sample, the RNeasy Mini spin column was transferred to a new 1.5 ml eppendorf tube. 20
µL RNase-free water was then added directly to the spin column membrane. The tubes were then centrifuged for 1 min at 8000xg to elute the RNA. This step was then repeated a second time.
The RNA samples were then capped and incubated at 65˚C × 5 minutes to denature the RNA and then chilled immediately on wet ice for 2-3 minutes.
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Fine mapping and credible set analysis of IGF2-INS-TH locus
In order to better characterize both the primary and the secondary signal, we performed a credible set analysis of the two regions, after integrating the exome chip results with Omni 2.5 Illumina array genotypes that were available for the majority of the samples (1), and exome-sequencing data that was available for 41% of the samples (2)genotyped by exome-chip. We imputed both exomeseq and 1000G (phase 3, release June 2014) variants into the samples that did not have wholeexome sequencing information, and only 1000G (phase 3) variants into the samples that had wholeexome sequencing, OMNI2.5 and exome chip genotypes. We then performed the association testing separately of each dataset and meta-analyzed both results (Supplementary Figure 1) . We used this IGF2 loss-of-function T2D protective variant data as input to perform the credible set analysis, following the previously described methodology (40). The splice site variant (rs149483638) ranked first according to its posterior probability, being the one with the highest prior of being the causal variant (Supplementary Figure 2) .
When conditioning for these two KCNQ1 variants and the rs149483638 in order to identify secondary signals, we identified another independent association with rs10770141 (OR=1.14; p=3×10 -4 ) located at the promoter region of TH gene. This variant was previously reported in a gene-centric meta-analysis (41). When meta-analyzing our data with those of this study, rs10770141 resulted in a novel GWAS significant signal, which was independent of the first splicesite variant in IGF2 (OR=1.08 (1.05-1.11); p=1.1×10 -9 ) (Supplementary Figure 1) .
We also used the fraction of the dataset for which we had exome-sequencing data in order to discard if rare variants with a strong effect size are the cause of a "synthetic association" (42), i. e.
that rare variants with large effect size, are responsible for the association signal found in the common variant (rs149483638). For this purpose, we performed multiple regression analyses introducing the rare variants as covariates, to test if this caused a loss of the association signal in rs149483638. This analysis confirmed that we were not in front of a synthetic association, as at least 31 rare variants had to be excluded in order to dilute the signal of the rs149483638 variant (Supplementary Figure 3) .
Credible set analysis
The credible set analysis were constructed as described in (40). Briefly, for each association analyses results, we computed an approximate Bayes factor for each variant, IGF2 loss-of-function T2D protective variant
assuming that the prior on beta is Gaussian and variance 0.04. Then, a posterior probability for each variant was computed dividing the ABF by the total number of variants in the region. Then the cumulative posterior probability was computed and all the variants in the 95% credible set interval were selected and included in the credible set. Assuming that we had two independent signals in the IGF2 region, we computed a first credible set conditioning on the two KCNQ1 T2D associated variants (rs139647931 and rs2237897) and the rs4929965, and a second credible set conditioning on rs149483638 variant and the two KCNQ1 T2D associated variants (rs139647931 and rs2237897). We selected all the variants that showed an r-squared higher than 0.1 with the top variants in each of the regions to compute the credible set analysis. *SAFS where analyzed by a family-based association test (FBAT) and where not included in the inverse-variance fixed effects meta-analyses. Since diabetes incidence in the DPP was computed by Hazard Ratios (HR), the results from the DPP were only included in the sample size meta-analysis. 
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